Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
11/20/17U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy
– Designation Based on Positive APOLLO Phase 3 Study – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 20, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of adults with hereditary transthyretin-mediat... 
Printer Friendly Version
11/16/17Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
− Company Plans to Complete Submission by Year-End − CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 16, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR), for the treatment of hereditary ATTR... 
Printer Friendly Version
11/16/17Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 16, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of its previously announced underwritten registered public offering of 6,440,000 shares of its common stock, including 840,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $125.00 per share. The aggregate ... 
Printer Friendly Version
11/13/17Alnylam Pharmaceuticals Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 13, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten registered public offering of 5,600,000 shares of its common stock at a public offering price of $125.00 per share. The gross proceeds to Alnylam from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expecte... 
Printer Friendly Version
11/13/17European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis
− Company on Track to Submit Marketing Authorization Application (MAA) and New Drug Application (NDA) at Year-End 2017 − CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 13, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment for patisiran, an investigational RNAi ... 
Printer Friendly Version
11/13/17Alnylam Pharmaceuticals Announces Proposed Public Offering of $675,000,000 of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 13, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $675,000,000. All of the shares in the offering are to be sold by Alnylam. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Barclays Capital Inc. are acti... 
Printer Friendly Version
11/09/17Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia
− Alignment Reached with FDA on Amended Safety Measures and Risk Mitigation Strategy to Enable Resumption of Fitusiran Clinical Program − − Reinitiation of Dosing Targeted Around Year-End − CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a successful Type A meeting with the U.S. Food and Drug Administration (FDA) where alignment was a... 
Printer Friendly Version
11/07/17Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
− ENVISION will Include Interim Analysis with Reduction of Urinary Aminolevulinic Acid (ALA) as Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit − – Company Expects to Report Interim Analysis Results in Mid-2018 and to File NDA at or Around Year-End 2018, Representing Significant Program Acceleration – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 7, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi... 
Printer Friendly Version
11/07/17Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity
– Reported Positive APOLLO Phase 3 Results for Patisiran, with Plans for First New Drug Application (NDA) Filing by Year-End – – Advanced Four RNAi Therapeutics in Late-Stage Development, Including Initiation of ENVISION Phase 3 Study for Givosiran in Acute Hepatic Porphyrias – – Maintained Strong Balance Sheet with $1.15 Billion in Cash and Plans to End 2017 with Greater than $1 Billion in Cash – CAMBRIDGE, Mass.--(BUS... 
Printer Friendly Version
11/03/17Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 (PH1)
– Lumasiran Achieves Substantial Reductions in Urinary Oxalate Levels in all Patients, Highlighting Potential of Substrate Reduction Therapy in PH1 through RNAi-mediated Glycolate Oxidase (GO) Inhibition – – Lumasiran Generally Well Tolerated with No Treatment-Related Serious Adverse Events or Study Discontinuations up to Seven Months from Initial Dosing – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 3, 2017-- Alnylam Pharmaceuticals... 
Printer Friendly Version
11/02/17Alnylam and Sanofi Present Positive Complete Results from APOLLO Phase 3 Study of Investigational Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
– Patisiran Meets Primary Endpoint with a 34.0 Point Mean Difference Relative to Placebo and a Negative 6.0 Point Mean Change (Improvement) Relative to Baseline in Modified Neuropathy Impairment Score (mNIS+7) at 18 Months – – Patisiran Meets All Secondary Endpoints, Including a 21.1 Point Mean Difference Relative to Placebo and a Negative 6.7 Point Mean Change (Improvement) Relative to Baseline in Norfolk-Quality of Life-Diabetic Neuropat... 
Printer Friendly Version
10/31/17Alnylam to Webcast Presentations at Upcoming November Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 31, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 26th Annual Credit Suisse Healthcare Conference on Wednesday, November 8, 2017 at 8:40 am MT (10:40 am ET) at the Phoenician Hotel in Scottsdale, Arizona 29th Annual Piper Jaf... 
Printer Friendly Version
10/30/17Alnylam to Webcast Conference Call Discussing Third Quarter 2017 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 30, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2017 on Tuesday, November 7, 2017, after the U.S. financial markets close. Management will provide an update on the Company and discuss third quarter 2017 results as well as expectations for the future via ... 
Printer Friendly Version
10/20/17Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors
– Company to Host Conference Call on Thursday, November 2, 2017, at 12:30 pm ET to Discuss Results – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 20, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the results of the APOLLO Phase 3 study of patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy, as well as additional posters on patisiran and hATTR amyloido... 
Printer Friendly Version
10/18/17Alnylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Diseases
– Agreement Includes Investigational RNAi Therapeutic Program for Hepatitis B Virus Infection and Discovery Collaboration on Additional Development Candidates for Treatment of Infectious Diseases – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 18, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an exclusive licensing agreement with Vir Biotechnology, a company dedicated to transforming the ... 
Printer Friendly Version
09/26/17Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS)
– Company Expects to Report Initial Patient Data in 2018 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 26, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 2 clinical study with cemdisiran (formerly known as ALN-CC5), a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseas... 
Printer Friendly Version
09/25/17Alnylam Continues Leadership in RNAi Technologies and Delivery with New Pre-Clinical Data Presented on "Enhanced Stabilization Chemistry Plus" (ESC+) GalNAc-siRNA Conjugate Platform at 13th Annual Meeting of the Oligonucleotide Therapeutics Society
– ESC+ Platform Incorporates Novel Design Features, Including Glycol Nucleic Acid (GNA) Modifications, that Confer Greater Specificity, Further Improving Already Wide Therapeutic Index by Over 6-fold – – First ESC+ Development Candidate, ALN-AAT02, in Development for Treatment of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease, Expected to Enter Clinical Trials in 2018 – CAMBRIDGE, Mass.--(B... 
Printer Friendly Version
09/20/17Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
– Investigational RNAi Therapeutic Patisiran Meets Primary and All Secondary Endpoints, with Highly Significant Reduction In Neuropathy Progression and Improvement in Quality of Life at 18 Months Relative to Placebo – – Alnylam Intends to File New Drug Application (NDA) in Late 2017 and Marketing Authorisation Application (MAA) in Early 2018 – – Full Results to be Presented at 1st European ATTR Amyloidosis Meeting in November – ... 
Printer Friendly Version
09/07/17Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi Therapeutic Programs
– Company Suspends Fitusiran Dosing due to Thrombotic Event and Aims to Resume Dosing as Soon as Possible upon Agreement with Global Regulatory Authorities – – Company Achieves Alignment with FDA on Givosiran Phase 3 Program Design, Including Interim Analysis Based on Reduction of Urinary Aminolevulinic Acid (ALA) as Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit – – New Givosiran Phase 3 Plan Enables Potential fo... 
Printer Friendly Version
09/05/17Alnylam to Webcast Presentation at 15th Annual Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 5, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the 15th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2017 at 9:55 am ET at the Grand Hyatt in New York City. A live audio webcast of the presentation will be available on the Investors section of the... 
Printer Friendly Version
08/09/17Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity
- Advanced Industry-Leading RNAi Therapeutics Pipeline, Including Four Programs in Late-Stage Development - - On Track to Report APOLLO Phase 3 Top-Line Results for Patisiran in Near Term, and Initiated ATLAS Phase 3 Program for Fitusiran - - Maintained Strong Balance Sheet with $1.25 Billion in Cash and Plans to End 2017 with Greater than $1.0 Billion in Cash - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 9, 2017-- Alnylam P... 
Printer Friendly Version
08/01/17Alnylam to Webcast Conference Call Discussing Second Quarter 2017 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 1, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2017 on Wednesday, August 9, 2017, after the U.S. financial markets close. Management will provide an update on the company and discuss second quarter 2017 results as well as expectations for the future via c... 
Printer Friendly Version
07/27/17Alnylam to Host Fourth Annual “RNAi Roundtable” Webcast Series
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 27, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it plans to host its 4th annual series of “RNAi Roundtable” webcasts this summer and early fall. The 2017 series will offer a range of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in many of the Company’s late-... 
Printer Friendly Version
07/10/17Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors
– With up to 20 Months of Dosing, Fitusiran Safety and Tolerability Profile Remains Encouraging – – Once Monthly, Subcutaneous Fitusiran Achieves Median Annualized Bleeding Rate (ABR) of One for All Patients and Zero for Patients with Inhibitors in Exploratory Post-hoc Analysis – – New England Journal of Medicine Publishes Phase 1 Clinical Results with Fitusiran in Patients with Hemophilia A and B without Inhibitors – – Aln... 
Printer Friendly Version
07/07/17Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors
– ATLAS to Evaluate Safety and Efficacy of Fitusiran Across Broad Spectrum of Patients Living with Hemophilia – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 7, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the initiation of the ATLAS Phase 3 clinical program for fitusiran. The global, multicenter program is des... 
Printer Friendly Version
06/26/17Alnylam Reports New Positive Clinical Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
– In Randomized, Double-Blind, Placebo-Controlled Study, Givosiran Demonstrates Decreased Annualized Attack Rate and Hemin Usage – – Initial Results from Ongoing Open Label Extension (OLE) Study Show Consistent Reductions in Porphyria Attacks with Continued Givosiran Treatment – – Givosiran Administration Generally Well Tolerated with Treatment up to 12 Months – – Company Plans to Initiate Phase 3 Clinical Program in Late 2... 
Printer Friendly Version
06/26/17Alnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis (ISTH) Congress
– New Data from an Ongoing Phase 2 Open-label Extension Study with Fitusiran in Patients with Hemophilia A and B, With or Without Inhibitors– CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 26, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that new results from an ongoing Phase 2 open-label extension (OLE) study wi... 
Printer Friendly Version
06/19/17Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 19, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that Chief Executive Officer John Maraganore, Ph.D., has been elected as the Chair of the Biotechnology Innovation Organization (BIO) Board of Directors for the 2017-2018 term. “BIO has long supported the innovative, transformative work of the biotech community, and it is an honor to serve a... 
Printer Friendly Version
06/12/17Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office
– McSwiggen '354 Covers Single-Stranded RNA Therapeutics Targeting Transthyretin – – Manoharan '612 Covers RNA Therapeutics of Any Length with GalNAc Conjugates of Any Valency – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 12, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for two pat... 
Printer Friendly Version
06/07/17Alnylam Expands Third Annual “Helping Hands” Community Service Day Globally to Benefit 18 Organizations
- Alnylam Supports Local Organizations in the Greater Boston Area, Maidenhead, UK and Zug, Switzerland - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 7, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today kicked off its third annual company-wide “Helping Hands” Community Service Day benefiting 18 organizations in the Greater Boston area, Maidenhead, UK and Zug, Switzerland. Employees are encouraged to ... 
Printer Friendly Version
05/31/17FDA Grants Breakthrough Therapy Designation for Alnylam’s Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria
– Additional Phase 1 Results to be Presented at the International Congress on Porphyrins and Porphyrias (ICPP), June 25 - 28, 2017 – – Company Plans to Initiate Phase 3 Clinical Program in Late 2017 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 31, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has received Breakthrough Therapy designation from the U.S. Food and Drug Admin... 
Printer Friendly Version
05/30/17Alnylam to Webcast Presentation at Jefferies 2017 Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 30, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies 2017 Healthcare Conference on Tuesday, June 6, 2017 at 9:00 am ET in New York City. A live audio webcast of the presentation will be available on the Investors section of the company’s website, www.alnylam.com. A replay ... 
Printer Friendly Version
05/24/17Alnylam Pharmaceuticals Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $71.87 per share. The gross proceeds to Alnylam from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to b... 
Printer Friendly Version
05/23/17Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 23, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock. In addition, Alnylam has granted the underwriter of the offering a 30-day option to purchase up to an additional 750,000 shares of its common stock solely to cover over-allotments. All of the shares in the o... 
Printer Friendly Version
05/12/17Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has granted stock options to Manmeet S. Soni, the Company's newly appointed Chief Financial Officer. The compensation committee of Alnylam's board of directors approved the grant, effective as of May 8, 2017, to Mr. Soni of non-qualified stock options to purchase an aggregate of 150,000 shar... 
Printer Friendly Version
05/10/17Alnylam to Webcast Presentations at Upcoming May Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday, May 18, 2017 at 8:40 am PT (11:40 am ET) at the Encore at Wynn Las Vegas in Las Vegas, Nevada, and at the UBS Global Healthcare Conference on Wednesday, May 24, 2017 at 10:00 a... 
Printer Friendly Version
05/09/17Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders
– Company Appoints Chief Financial Officer and Other Key Roles Ahead of Anticipated Transition to Commercialization – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today the appointment of several experienced industry leaders to key leadership roles including: Manmeet S. Soni, Chief Financial Officer; Theresa Heggie, Senior Vice President, Head of ... 
Printer Friendly Version
05/05/17Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity
– Advanced Industry-Leading RNAi Therapeutics Pipeline with Eight Clinical Programs, Including Three Programs in Late-Stage Development – – Maintained Strong Balance Sheet with $962 Million in Cash and Plans to End 2017 with Greater than $700 Million in Cash – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 5, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial re... 
Printer Friendly Version
04/27/17Alnylam to Webcast Conference Call Discussing First Quarter 2017 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 27, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2017 on Friday, May 5, 2017, before the U.S. financial markets open. Management will provide an update on the company and discuss first quarter 2017 results as well as expectations for the future via confere... 
Printer Friendly Version
04/26/17Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
– Patisiran Achieves Mean 7.0 Point Decrease in Modified Neuropathy Impairment Score (mNIS+7), Comparing Favorably with Expected Mean 26-30 Point Increase Estimated from Historical Data – – In New Post-Hoc Analysis, Evidence for Potential Halting or Improvement of Neuropathy Progression Seen Across Broad Range of Baseline Neuropathy Severity – – In Addition, Company Reports First-Ever Histological Evidence for Decrease in Dermal TT... 
Printer Friendly Version
04/26/17The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
— Pivotal trials will enroll approximately 1,500 subjects randomized to inclisiran versus approximately 1,500 subjects randomized to placebo, with a primary endpoint of LDL-C and an 18-month study period — — NDA submission anticipated at or around the end of 2019 — PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2017-- The Medicines Company (NASDAQ:MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) today announced that T... 
Printer Friendly Version
03/28/17Alnylam to Webcast Presentation at 16th Annual Needham Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 11:20 am ET at the Westin Grand Central Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the c... 
Printer Friendly Version
03/01/17Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for givosiran (ALN-AS1), an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias. The purpose of the PRIME initiative is to b... 
Printer Friendly Version
02/28/17Alnylam Acknowledges Rare Disease Day by Highlighting Services to Aid in Rare Disease Diagnosis
– Alnylam Act™ sponsors free third-party genetic counseling and testing services for people at risk for hereditary ATTR amyloidosis (hATTR amyloidosis) – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 28, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today marked the 10th annual Rare Disease Day by underscoring its commitment to enabling diagnosis for people and caregivers impacted by specific rare ... 
Printer Friendly Version
02/27/17Alnylam to Webcast Presentations at Upcoming March Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Cowen and Company 37th Annual Healthcare Conference on Monday, March 6, 2017 at 2:40 pm ET at the Boston Marriott Copley Place Hotel in Boston, Massachusetts and at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 9:30 am ... 
Printer Friendly Version
02/10/17Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the compensation committee of Alnylam's board of directors, which is composed entirely of independent directors, approved a grant, effective as of February 6, 2017, to a vice president level employee of the Company, of a non-qualified stock option to purchase 50,000 shares of Alnylam's common s... 
Printer Friendly Version
02/07/17Alnylam to Webcast Presentation at Leerink Partners 6th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 2:30 pm ET at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investor... 
Printer Friendly Version
02/02/17Alnylam Presents New Data on Fitusiran at EAHAD
– New Phase 1 Results Demonstrate Effective Bleed Management with Replacement Factor and Bypassing Agents During Fitusiran Administration – – Stability Study Results Support a Greater than Two Year Product Shelf-Life at Room Temperature Storage Conditions – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company today announced new results from... 
Printer Friendly Version
02/01/17Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2016 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2016 on Wednesday, February 8, 2017, after the U.S. financial markets close. Management will provide an update on the company and discuss fourth quarter and year-end 2016 results as well as expectations... 
Printer Friendly Version
01/03/17Alnylam to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco. In addition, the company will webcast the Q&A breakout session immediately following its present... 
Printer Friendly Version
01/03/17Alnylam Announces Management Change and Key Promotion
– Company Announces Departure of Chief Business Officer and Promotion of Pushkal Garg, M.D., to Chief Medical Officer – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that David-Alexandre "DA" Gros, M.D., Senior Vice President and Chief Business Officer, plans to leave the company for personal reasons. His resignation will be effective... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.